EMA Recommends Treatment for Maple Syrup Urine Disease
MSUD is a rare genetic disorder of BCAA metabolism. In this condition, buildup of toxic metabolites from BCAAs produced from protein breakdown leads to significant and potentially irreversible developmental effects. It may cause metabolic derangements, cerebral edema, seizures, coma, and respiratory failure, and it may be fatal. It affects fewer than 0.1 in 10,000 people in the EU, equivalent to fewer than 5000 people.
This is below the ceiling for orphan drug designation (5 in 10,000). In 2020, the EMA granted orphan designation to a solution of amino acids not containing any BCAAs, intended to be given by infusion to replace other sources of amino acids. At the time, the EMA said, there were no suitable treatments authorized in the EU for MSUD, and patients were managed with strict diets to control the amount of BCAAs taken in from proteins. Some forms of the disorder also responded to vitamin B supplements. Some patients needed hospitalization for enteral feeding or procedures to filter BCAAs directly from the blood. Other patients were judged suitable for liver transplantation, which restores the ability to break down BCAAs.
Medicine Reduces Harmful Amino Acids
Maapliv, manufactured by Recordati Rare Diseases, is a combination of amino acids free of BCAA. It is used as a solution for infusion in combination with carbohydrate and lipid supplementation to prevent or reverse protein catabolism and promote anabolism in patients with MSUD decompensation, thereby reducing harmful alpha-keto acid levels.
The CHMP said that leucine normalization had been shown in patients with MSUD decompensation who are given Maapliv in five scientific publications that reported on parenteral use of BCAA-free solutions with the same formulation as Maapliv. Treatment with Maapliv should be initiated under the supervision of a physician experienced in the management of MSUD disease.
Detailed recommendations for the use of Maapliv will be described in the summary of product characteristics, which will be published on the EMA website in all official European Union languages after the marketing authorization has been granted by the European Commission.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Pharmacy warning of unsustainable demand for weight loss medication
The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'
Yahoo
7 hours ago
- Yahoo
Brains Aged Faster In 2021–2022: What Did The Pandemic Do To Us?
A new study suggests that the pandemic may have had a significant impact on our brains, whether or not we contracted COVID-19. Leveraging an extensive database of brain scans, British researchers say that people's brains showed accelerated aging during 2021 and 2022, including signs of shrinkage. While people who were infected with COVID also showed cognitive decline, like slower processing speed, the study was notable because it said even the non-infected were likely to experience harm to their brain. While the study did not delve into the exact causes of the accelerated aging, the study's first author, Ali-Reza Mohammadi-Nejad, a neuroimaging researcher at the University of Nottingham, theorizes that it may have been the result of stress and other factors. 'But it is likely that the cumulative experience of the pandemic—including psychological stress, social isolation, disruptions in daily life, reduced activity and wellness—contributed to the observed changes… In this sense, the pandemic period itself appears to have left a mark on our brains, even in the absence of infection,' said Mohammadi-Nejad, per NBC. The researchers found that males and 'those from more socioeconomically deprived backgrounds' experienced the most significant brain aging. Overall, the pandemic was thought to be linked to a 5.5-month acceleration in the aging process. This is not the first time researchers have reached similar conclusions. Last year, a previous study found that teenagers experienced dramatic brain aging during the pandemic. Notably, the study suggested that girls' brains aged 4.2 years faster and boys' brains aged 1.3 years faster, on average. The latest study does not indicate whether the structural changes identified in individuals who have never contracted COVID will result in any noticeable changes in brain function. Nor does the study confirm whether the physical changes will persist over the long term, says Adam Brickman, a professor of neuropsychology at Columbia University Vagelos College of Physicians and Surgeons, who was not involved in the study.
Bloomberg
7 hours ago
- Bloomberg
Roche to Test Whether New Drug Can Prevent Alzheimer's Disease
Roche Holding AG plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, its latest investment in one of the most failure-prone areas of drugmaking. The new late-stage study will focus on people who are at risk of cognitive decline, Roche said in a statement late Sunday. The goal would be to slow down the emergence of symptoms, or prevent them entirely.
